Cleerly to Showcase New AI-QCT Research at SCCT2025 Annual Meeting

New Insights on AI-Quantitative Coronary CT (AI-QCT) Data to be Shared in Montreal, July 17-20, 2025

DENVER--(BUSINESS WIRE)--Cleerly, the leader in advanced cardiovascular imaging, will be presenting new research at the Society of Cardiovascular Computed Tomography (SCCT) Annual Meeting 2025. The conference will take place July 17-20, 2025, at the Palais des Congrès de Montréal in Montreal, Canada. This annual event brings together leading cardiovascular imaging specialists, researchers, and technology innovators from around the world to share the latest advances in cardiovascular computed tomography.

Cleerly will be sharing findings on three scientific abstracts: an investigation into how AI-QCT influences physician prescribing practices, a pooled analysis comparing AI-QCT ISCHEMIA accuracy to alternative measurements, and a pooled analysis, per-vessel comparison of AI-QCT ISCHEMIA to alternative measurements. Please see Cleerly's full conference program schedule below.

• Thursday, July 17:
  • AI/ML Interactive Workshop (8:00 a.m. to 4:30 p.m.). An interactive small-group workshop featuring insights from imaging, AI, and data science leaders, including Cleerly's Udo Hoffmann, MD and James K. Min, MD, FACC, FESC, MSCCT. Designed for healthcare professionals at every career stage in cardiovascular imaging.
  • Seeing More of What Matters: Hands-On AI-Powered CT Workshop hosted by Cleerly (5:00 p.m. to 8:00 p.m.). Get hands-on experience with Cleerly LABS through live case reviews, guided software use, and clinical challenges. Topics include plaque analysis, ISCHEMIA, COMPARE, CT-guided PCI, and more. Speakers include Udo Hoffmann, MD, Sarah Bär, MD, PhD, Maros Ferencik, MD, PhD, MCR, MSCCT. John Osborne, MD, PhD, FACC, FNLA, Yader Sandoval, MD, FACC, FSCAI, FESC, and Amro Alsaid, MD, FACC, FASE, FSCMR. Todd C. Villines, MD, FSCCT, will moderate. Registration is open and a complimentary dinner is included.
• Friday, July 18:
  • Diagnostic Performance of AI-QCT Ischemia Compared with FFR-CT: A Pooled Analysis of Patient and Vessel Level Ischemia Poster Session 2 (9:30 a.m. to 10:15 a.m.) with Tyler Coombes, MD.
  • Diagnostic Accuracy of a Novel Atherosclerotic Imaging-Ischemia Algorithm According to Fractional Flow Reserve Ranges from a Pooled Analysis Poster Session 2 (9:30 a.m. to 10:15 a.m.) with Hyung-Bok Park, MD, PhD.
  • Novel Technologies Session (5:05 p.m. to 6:15 p.m.) James K. Min, MD, FACC, FESC, MSCCT, Founder and CEO of Cleerly, presents "Imaging that Informs the Future: AI-Powered Precision in Cardiovascular CT." This unopposed session explores the future of cardiovascular CT technology and precision imaging.
• Saturday, July 19:
  • Impact of Atherosclerosis Imaging-Quantitative Computed Tomography on Medical Treatment Recommendations vs. Real-World Prescriptions Poster Session 18 (10:40 a.m. to 11:30 a.m.) with Sophie Cramer, MD. See how advanced atherosclerosis imaging influences treatment decisions and compare recommendations with real-world prescribing patterns.
  • COMPARE Lunch Symposium (12:45 p.m. to 1:45 p.m.). A case-based session to see how Cleerly's advanced plaque imaging goes beyond traditional metrics. Learn why LDL alone misses risk, explore disease tracking with COMPARE, and tackle real cases in interactive "What would you do?" scenarios like when calcium scores are zero. Speakers include James Min, MD, FACC, FESC, MSCCT, John Osborne, MD, PhD, FACC, FNLA, and Marc Bonaca, MD, MPH. Ricardo Cury, MD, FSCCT, and Maros Ferencik, MD, PhD, MCR, MSCCT, will moderate the session.
  • "Meet Cleerly Leadership" Reception (3:30 p.m. - 4:30 p.m.) Heart-healthy refreshments and networking with Cleerly's executive team at Cleerly’s booth #505.

Stop by and learn more about Cleerly at booth #505. To see a full schedule of Cleerly presentations or schedule a meeting with Cleerly leadership, please visit this link.

About Cleerly

Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced noninvasive CT imaging. Cleerly’s approach is grounded in science, based on millions of images from over 40,000 patients. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: cleerlyhealth.com.